Investor Information
Latest News
-
Indivior Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for SUBOXONE® (buprenorphine and naloxone) Sublingual Film
June 18, 2019 | PDF Version
-
New Data from the RECOVER™ Study Reports on Abstinence, Drug Craving and Psychosocial Outcomes in People with Opioid Use Disorder following Transition from a Clinical Trial to the Real-World Setting
June 17, 2019 | PDF Version
-
Jefferies 2019 Global Healthcare Conference Presentation
June 4, 2019 | PDF Version
-
Indivior to present at Jeffries 2019 Healthcare Conference
May 16, 2019 | PDF Version
Our Commitment
Updates on the Department of Justice Action
Get updates and information on Indivior’s ongoing response to the recent action by the U.S. Department of Justice and learn about the company’s unwavering commitment to patients, doctors, and communities fighting opioid addiction.
See more >
Upcoming Events
Webcasts/Audiocasts/Presentations
Click on the headings to view online or download a presentation:
RNS Filings
View Indivior filings with the Regulatory News Service on regulatory and non-regulatory updates.
